ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients
Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with...